| Year |
Citation |
Score |
| 2011 |
Hudzik TJ, Maciag C, Smith MA, Caccese R, Pietras MR, Bui KH, Coupal M, Adam L, Payza K, Griffin A, Smagin G, Song D, Swedberg MD, Brown W. Preclinical pharmacology of AZD2327: a highly selective agonist of the δ-opioid receptor. The Journal of Pharmacology and Experimental Therapeutics. 338: 195-204. PMID 21444630 DOI: 10.1124/Jpet.111.179432 |
0.38 |
|
| 2011 |
Black PC, Brown GA, Dinney CP, Kassouf W, Inamoto T, Arora A, Gallagher D, Munsell MF, Bar-Eli M, McConkey DJ, Adam L. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. The Journal of Urology. 185: 693-700. PMID 21168861 DOI: 10.1016/J.Juro.2010.09.082 |
0.304 |
|
| 2008 |
Grespin ME, Bonamy GM, Roggero VR, Cameron NG, Adam LE, Atchison AP, Fratto VM, Allison LA. Thyroid hormone receptor alpha1 follows a cooperative CRM1/calreticulin-mediated nuclear export pathway. The Journal of Biological Chemistry. 283: 25576-88. PMID 18641393 DOI: 10.1074/jbc.M710482200 |
0.3 |
|
| 2006 |
Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4671-7. PMID 16899617 DOI: 10.1158/1078-0432.Ccr-06-0407 |
0.317 |
|
| 2006 |
Harmer NJ, Robinson CJ, Adam LE, Ilag LL, Robinson CV, Gallagher JT, Blundell TL. Multimers of the fibroblast growth factor (FGF)-FGF receptor-saccharide complex are formed on long oligomers of heparin. The Biochemical Journal. 393: 741-8. PMID 16223363 DOI: 10.1042/BJ20050985 |
0.318 |
|
| 2005 |
Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Research. 65: 10524-35. PMID 16288045 DOI: 10.1158/0008-5472.Can-05-1536 |
0.317 |
|
| 2005 |
Villemure JF, Adam L, Bevan NJ, Gearing K, Chénier S, Bouvier M. Subcellular distribution of GABA(B) receptor homo- and hetero-dimers. The Biochemical Journal. 388: 47-55. PMID 15617512 DOI: 10.1042/Bj20041435 |
0.676 |
|
| 2003 |
Perroy J, Adam L, Qanbar R, Chénier S, Bouvier M. Phosphorylation-independent desensitization of GABA(B) receptor by GRK4. The Embo Journal. 22: 3816-24. PMID 12881416 DOI: 10.1093/Emboj/Cdg383 |
0.668 |
|
| 1999 |
Loisel TP, Ansanay H, Adam L, Marullo S, Seifert R, Lagacé M, Bouvier M. Activation of the beta(2)-adrenergic receptor-Galpha(s) complex leads to rapid depalmitoylation and inhibition of repalmitoylation of both the receptor and Galpha(s). The Journal of Biological Chemistry. 274: 31014-9. PMID 10521499 DOI: 10.1074/Jbc.274.43.31014 |
0.73 |
|
| 1999 |
Adam L, Bouvier M, Jones TL. Nitric oxide modulates beta(2)-adrenergic receptor palmitoylation and signaling. The Journal of Biological Chemistry. 274: 26337-43. PMID 10473590 DOI: 10.1074/jbc.274.37.26337 |
0.541 |
|
| 1998 |
Hebert TE, Loisel TP, Adam L, Ethier N, Onge SS, Bouvier M. Functional rescue of a constitutively desensitized beta2AR through receptor dimerization. The Biochemical Journal. 330: 287-93. PMID 9461522 DOI: 10.1042/Bj3300287 |
0.694 |
|
| 1996 |
Loisel TP, Adam L, Hebert TE, Bouvier M. Agonist stimulation increases the turnover rate of beta 2AR-bound palmitate and promotes receptor depalmitoylation. Biochemistry. 35: 15923-32. PMID 8961959 DOI: 10.1021/Bi9611321 |
0.722 |
|
| 1996 |
Moffett S, Adam L, Bonin H, Loisel TP, Bouvier M, Mouillac B. Palmitoylated cysteine 341 modulates phosphorylation of the beta2-adrenergic receptor by the cAMP-dependent protein kinase. The Journal of Biological Chemistry. 271: 21490-7. PMID 8702933 DOI: 10.1074/Jbc.271.35.21490 |
0.669 |
|
| Show low-probability matches. |